The Canadian Prevention of Renal and Cardiovascular Endpoints Trial
Recruitment status was Recruiting
Advanced kidney disease with it's associated heart and blood vessel problems are becoming more frequent. These problems markedly affect length and quality of life and cost a lot to treat. Treatments are known that can prevent development of advanced kidney and heart disease. These treatments are not being optimally applied in the current health system. This study aims to identify people with relatively early stage chronic kdiney disease. With the participation of these people, the study will test whether a nurse co-ordinated clinic involving a medical kidney specialist, applying the known treatments, can reduce or delay the onset of advanced kidney disease and heart and blood vessel problems such as heart attack, stroke and death, to a greater extent than usual care. The study will also address issues of costs associated with care and illness. The nature of the care provided by the heatlh care professionals will be studied to see how best to achieve good health outcomes.
Chronic Kidney Disease
Procedure: Combined CKD and CVD Prevention
Procedure: Cardiovascular Disease prevention
Procedure: Treatment of Chronic Kidney Disease complications
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial|
- Time to major cardiovascular event(myocardial infarction, stroke, coronary or peripheral revascularization, hospitalization for heart failure or unstable angina, or death due to cardiovascular cause)
- - Time to first major clinical event (ESRD, non-fatal cardiovascular events as in secondary (a) or all cause death)
- • # patients screened via lab
- • # patients seen meeting eligibility criteria
- • # patients enrolled over documented period
- • OR similar assessment of the success of recruitment if non-laboratory based
- • Description of baseline characteristics including care in place at study entry to compare to existing databases on clinic patients and community data
- • Description of how the intervention is applied (by chart review, interviews and activity records)
- • Assessment of the workload and study staff requirements
- • The % of patients having a cardiovascular or kidney related clinical outcome event by one and two years of study
- • The % of patients lost to follow-up each year from the experimental and control groups
- • The % of patients in the experimental and control groups achieving targets for blood pressure, lipids, diabetes control, anemia, and mineral metabolism at six months, one and two years.
- • The % of patients in the experimental and control groups smoking at six months, one and two years.
- • The quality of life of those in the experimental and control groups at baseline, six, twelve and 24 months.
- • The satisfaction with care received in the experimental and control groups
|Study Start Date:||April 2005|
|Estimated Study Completion Date:||December 2007|
The pilot study is designed in two phases. The first phase is intended to provide data on some key points that need to be addressed prior to future funding applications to the CIHR and the NHLBI. These applications are currently tentatively planned for the fall of 2005. The second phase of the pilot study is intended to more completely establish the feasibility of successfully completing the full trial by examining the issue of contamination and the ability of the intervention to generate a difference between the groups with regard to use of efficacious therapies and control of modifiable risk factors, or intermediate variables on the causal pathway to the clinical end-points in the full-scale trial. The second phase will also address the need to describe the operation of the experimental intervention more thoroughly. Finally, the second phase of the pilot study will compare the randomized study groups with regard to short-term quality-of-life outcomes.
- How long does it take to recruit 100 patients per study site?
- What recruitment strategies are most efficient?
- How do the baseline characteristics of those recruited compare to referred populations, and to the general population with CKD?
- How do the nephrologist and nurse work together to provide care to those in the intervention group?
- What is the nature of the care provided by the nurses and physicians to those in the intervention group?
- Is the study nurse able to manage the patient load?
- How much time and resources are needed to a) provide care, b) to carry out study measurements?
- Can health care resources used be measured for economic analysis?
- What is the rate of loss to follow-up?
- What is the overall estimate of the primary outcome event rate?
By one year of follow-up, what is the difference between the study groups in terms of:
- Protocol interventions used (estimates contamination)
- Proportion i) smoking; and proportion achieving ii) BP, iii) lipid, iv) diabetes, v) anemia, vi) acidosis, vii) mineral metabolism targets
- Quality of Life
- Satisfaction with care andomized, parallel, two group, multicentre, clinical trial of people with CKD, with or without diabetes mellitus or proteinuria. The intention is to roll the pilot study into the full-scale trial if the pilot itself is deemed successful. A laboratory-based case finding method will be used preferentially to identify potential participants. This will be supplemented by practice-based case-finding approaches where necessary to ensure recruitment of a representative population. Randomization will be by a central computer-based telephone process. Stratification will be by center and presence of diabetes and proteinuria. The intervention consists of a protocol guided, multiple risk factor and chronic disease care model-like approach delivered by a trained nurse supported by a nephrologist and will be based in a nephrology clinic like setting.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00231803
|Contact: Brendan J Barrett, MD||(709) email@example.com|
|Contact: Patrick S Parfrey, MD||(709) firstname.lastname@example.org|
|Canada, British Columbia|
|St. Paul's Hospital||Not yet recruiting|
|Vancouver, British Columbia, Canada, V6Z 1Y6|
|Contact: Adeera Levin, MD (604)682-2344 ext 62262 email@example.com|
|Contact: Alexandra Kruthaup (604)682-2344 ext 62505 firstname.lastname@example.org|
|Sub-Investigator: Adeera Levin, MD|
|Canada, Newfoundland and Labrador|
|Memorial University of Newfoundland||Recruiting|
|St. John's, Newfoundland and Labrador, Canada, A1B 3V6|
|Contact: Brendan J Barrett, MD (709) 777-8073 email@example.com|
|Contact: Patrick S Parfrey, MD (709) 777-7261 firstname.lastname@example.org|
|Principal Investigator: Patrick S Parfrey, MD|
|Principal Investigator: Brendan J Barrett, MD|
|Canada, Nova Scotia|
|Capitol District Health Authority||Recruiting|
|Halifax, Nova Scotia, Canada, B3H 1V8|
|Contact: Steven Soroka, MD (902) 473-2099 email@example.com|
|Contact: Colleen D Wile (902) 473-7243 firstname.lastname@example.org|
|Sub-Investigator: Steven Soroka, MD|
|London Health Sciences Centre||Recruiting|
|London, Ontario, Canada, N6A 4G3|
|Contact: Amit Garg, MD (519)685-5000 ext 58502 Amit.Garg@lhsc.on.ca|
|Contact: Mary J Edgar (519)685-5000 ext 34769 email@example.com|
|Sub-Investigator: Amit Garg, MD|
|Charles LeMoyne Hospital||Recruiting|
|Greenfield Park, Quebec, Canada, J4V 2H1|
|Contact: Georges Soltys, MD (450) 466-5000 ext 2774 firstname.lastname@example.org|
|Contact: Michele Roy (450) 466-5000 ext 2471 email@example.com|
|Sub-Investigator: George Soltys, MD|
|Principal Investigator:||Patrick S Parfrey, MD||Memorial University of Newfoundland|
|Principal Investigator:||Brendan J Barrett, MD||Memorial University of Newfoundland|